← Back to Search

Alkylating Agent

Paclitaxel for Ovarian Cancer

Phase 1 & 2
Waitlist Available
Led By Robert A Burger
Research Sponsored by NRG Oncology
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights

Study Summary

This trial is studying side effects and the best dose of ruxolitinib when given with paclitaxel and carboplatin to treat patients with ovarian, fallopian tube, or primary peritoneal cancer.

Eligible Conditions
  • Ovarian Cancer
  • Peritoneal Cancer
  • Endometrioid Adenocarcinoma
  • Peritoneal Adenocarcinoma
  • Fallopian Tube Carcinoma
  • Fallopian Tube Cancer
  • Ovarian Carcinoma
  • Ovarian Adenocarcinoma
  • Peritoneal Serous Adenocarcinoma

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Incidence of hematologic (heme) dose-limiting toxicity (Phase I)
Secondary outcome measures
Complete pathological response (Phase II)
Frequency of patients who could not receive surgery within the defined timeframe for reasons other than non-response, disease progression, or medical contraindications (Phase I)
Incidence of adverse events (Phase I)
+4 more
Other outcome measures
Change in cancer stem cells (CSC) observed in tissue
Change in serum C-reactive protein (CRP)

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Arm II (ruxolitinib, paclitaxel, and carboplatin)Experimental Treatment4 Interventions
See Detailed Description.
Group II: Arm I (paclitaxel and carboplatin)Active Control3 Interventions
See Detailed Description.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Carboplatin
2014
Completed Phase 3
~6670
Paclitaxel
2011
Completed Phase 4
~5380
Ruxolitinib Phosphate
2011
Completed Phase 2
~390
Therapeutic Conventional Surgery
2005
Completed Phase 3
~9870

Find a Location

Who is running the clinical trial?

NRG OncologyLead Sponsor
232 Previous Clinical Trials
101,042 Total Patients Enrolled
National Cancer Institute (NCI)NIH
13,703 Previous Clinical Trials
40,931,603 Total Patients Enrolled
288 Trials studying Ovarian Cancer
73,651 Patients Enrolled for Ovarian Cancer
Robert A BurgerPrincipal InvestigatorNRG Oncology
1 Previous Clinical Trials
30 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
2016. "Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02713386.
All > Peritoneal Cancer
~17 spots leftby May 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top